A French team has put forward preliminary guidance for conducting phase 1 oncology clinical trials during the COVID-19 pandemic, including specific precautions for managing any participants with SARS-CoV-2.
The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.
Results from the COVID-19 and Cancer Consortium show that a variety of treatments for COVID-19 have no significant positive impact on 30-day mortality in patients with invasive cancer.
A post-hoc analysis of the BIG 1–98 trial has identified genetic variants associated with the risk for recurrence after 5 years of adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive, HER2-negative, early-stage breast cancer.
Supplementing capecitabine with neratinib instead of lapatinib is associated with a significant improvement in the progression-free survival of previously treated patients with metastatic HER2-positive breast cancer, shows the phase 3 NALA trial.